Skip to main content
. Author manuscript; available in PMC: 2023 Jan 27.
Published in final edited form as: Nat Immunol. 2022 Jul 28;23(8):1183–1192. doi: 10.1038/s41590-022-01274-3

Figure 2. aPD1 is associated with quantitatively similar but qualitatively worse anti-HA antibodies.

Figure 2.

A. HAI as fold-change at the late time point compared to baseline for each strain. Nominal P values from t-test comparisons are shown. B. Seroprotection for each strain, shown as the proportion of participants who achieved an HAI titer of 1:40 or higher 21–42 days after vaccination. C. Hemagglutinin inhibition titers determined for the H1N1, H3N2, and influenza B strains. (*P<0.05, **P<0.01, ***P<0.001; two-way ANOVA with Tukey’s). D. Proportion of anti-H1 IgG1 antibodies galactosylated (***P=1.8x10−12; two-way ANOVA with Tukey’s; comparison of aPD1 vs Healthy at baseline). E. Proportion anti-H1 antibodies galactosylated at baseline (P=3.4x10−9; t-test). F. Sialylation for anti-H1 IgG1 antibodies (**P=7.1x10−3; two-way ANOVA with Tukey’s; comparison of aPD1 vs Healthy at oneWeek). G. Proportion anti-H1 antibodies sialylated at baseline (P=0.02; t-test). H. Affinity determined as EC50/Kd (*P=0.02; two-way ANOVA with Tukey’s; comparison of aPD1 at baseline vs late).